ArticleProstate cancer and prostatic diseases2026
Oncological and functional outcomes of focal irreversible electroporation for localised prostate cancer: a single institution series of 171 cases.
Article in Prostate cancer and prostatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFocal irreversible electroporation (IRE) is an attractive choice for patients aiming to obtain local control of prostate cancer, while decreasing the postoperative risk of impotence and incontinence compared to whole-gland treatments.
methodsRetrospective review of a single centre prospective database of 171 consecutive primary IRE procedures for localised prostate cancer. Primary outcomes include oncological infield and out-of-field progression. Secondary objectives include post-IRE continence and impotence.
resultsThe median follow-up is 35 months (3-90 months). The median diameter of the treated lesions is 11 mm (4-24 mm). Most patients had PI-RADS 4-5 abnormalities on prostate MRI, and 25 patients (15%) had ISUP grade 4-5 cancer. Of the 135 patients with >12 months follow-up, 84 had a surveillance biopsy of whom 8.3% had significant infield persistence, with significant out-of-field cancer in 14.3%. There was no difference in the risk of infield cancer persistence regardless of the pre-IRE ISUP score (p = 0.8), or tumour location (p > 0.9). The presence of low volume out-of-field cancer at diagnosis did not increase the risk of post-IRE cancer persistence/progression (p = 0.7). The prostate PSMA PET SUVmax of ≥10 did not increase the risk of infield or out-of-field recurrence of cancer (p = 0.3). A PSAD > 0.15 did not increase the risk of infield persistence or out-of-field progression of cancer (p = 0.8). Urinary continence was maintained in 167/171 (97.6%), while erectile function was maintained in 94/112 (84%) of sexually active patients who completed questionnaires.
conclusionsOf the patients who proceeded to post-IRE biopsy, 92% had infield ablation of clinically significant cancer with a low risk of urinary incontinence or impotence. Focal IRE of prostate cancer has promising short to medium-term outcomes and is associated with low risks of impotence and incontinence. Long-term follow-up of out-of-field progression risk is required.
Identifiers
42680821What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.